KR20120117715A - Functional antibiotic complex composition for animal use - Google Patents
Functional antibiotic complex composition for animal use Download PDFInfo
- Publication number
- KR20120117715A KR20120117715A KR1020120109818A KR20120109818A KR20120117715A KR 20120117715 A KR20120117715 A KR 20120117715A KR 1020120109818 A KR1020120109818 A KR 1020120109818A KR 20120109818 A KR20120109818 A KR 20120109818A KR 20120117715 A KR20120117715 A KR 20120117715A
- Authority
- KR
- South Korea
- Prior art keywords
- weight
- parts
- animals
- antibiotic composition
- antibiotic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
본 발명은 페니실린과 스트렙토마이신의 동물용 복합 항생제인 PPS 항생제제의 페니실린 아나필락시스에 대한 안전성 및 대사기능성을 향상시킨 동물용 복합 기능성 항생제 조성물에 관한 것이다. 더욱 상세하게는 벤자틴 페니실린G, 프로카인 페니실린G 및 디히드로스트렙토마이신으로 이루어진 PPS 항생제제에 덱사메타손 및 부타포스판을 복합시킨 동물용 복합 기능성 항생제 조성물에 관한 것이다.
The present invention relates to a multifunctional antibiotic composition for animals having improved safety and metabolic function against penicillin anaphylaxis of PPS antibiotic agent, which is an animal combined antibiotic of penicillin and streptomycin. More specifically, the present invention relates to a multifunctional antibiotic composition for animals comprising a PPS antibiotic agent consisting of benzathine penicillin G, procaine penicillin G and dihydrostreptomycin, and dexamethasone and butafosan.
PPS 항생제제란 현재 국내에서 시판되고 있는 동물용 의약품 항생제제로서 1ml 주사제 내에 다음과 같은 성분을 지니는 항생제제를 의미한다. 벤자틴 페니실린G 수화물(Penicillin G Benzathine Hydrate) 100,000 IU; 프로카인 페니실린G (Penicillin G Procaine) 150,000 IU; 디히드로스트렙토마이신 황산염(Dihydrostreptomycin Sulfate) 200.0 mg(역가) 및 적량의 주사용수로 되어 있다.
The PPS antibiotic agent is an antibiotic agent for veterinary drugs currently marketed in Korea, and means an antibiotic agent having the following components in 1 ml of injection. Penicillin G Benzathine Hydrate 100,000 IU; Penicillin G Procaine 150,000 IU; 200.0 mg (potency) of dihydrostreptomycin sulfate and an appropriate volume of water for injection.
벤자틴 페니실린G와 프로카인 페니실린G는 벤질페니실린의 일종인 베타락탐계 항생물질로 다양한 그람 양성세균과 그람 음성세균에 대해 광범위하게 항균능력을 나타내며 디히드로스트렙토마이신은 아미노글리코사이드계 항생물질로 마이코박테리움속, 마이코플라즈마속 박테리아 및 그람 음성 간균 및 일부 황색포도상구균에 대해 효과적임이 알려져 있다. 따라서 PPS 항생제제는 상기 3성분의 항생물질을 복합화시킨 항생제제로서 다양한 병원성 박테리아에 항균 능력을 지닌 동물용 의약품으로 사용되어 왔다.
Benzaitin Penicillin G and Procaine Penicillin G are beta-lactam antibiotics, a type of benzylpenicillin, which has broad antibacterial activity against various gram-positive bacteria and gram-negative bacteria. Dihydrostreptomycin is an aminoglycoside antibiotic It is known to be effective against the genus Kobacterium, mycoplasma bacteria and gram negative bacilli and some Staphylococcus aureus. Therefore, PPS antibiotics have been used as antibiotic agents that combine the three components of antibiotics and have been used as veterinary drugs with antimicrobial activity against various pathogenic bacteria.
그러나 PPS 항생제제에 포함된 페니실린계 성분 등은 일부의 동물 개체에 페니실린 아나필락시스(anaphylaxis)를 유발할 수 있어 이를 예방할 수 있도록 통상 페니실린 아나필락시스의 치료제로 사용하는 부신피질호르몬제인 덱사메타손을 함께 병용 투여하는 경우도 있었다.
However, the penicillin-based components contained in PPS antibiotics may cause penicillin anaphylaxis in some animals, so that when combined with dexamethasone, a corticosteroid used as a therapeutic agent for penicillin anaphylaxis, there was.
이처럼 페니실린계 성분을 포함하는 항생제제와 덱사메타손을 함께 병용 투여하면 페니실린 아나필락시스를 예방할 수 있는 장점이 있으나 통상 부신피질호르몬제인 덱사메타손의 과잉 투여로 인해 생리활성 대사의 이상을 초래하여 대사 장애 및 성장 저해와 같은 문제가 발생할 수 있었던 것이다.
The combination of antibiotics containing dexamethasone and dexamethasone has the advantage of preventing penicillin anaphylaxis. However, overdose of dexamethasone, which is usually the adrenocortical hormone, causes abnormalities of physiological activity, leading to metabolic disturbance and growth inhibition The same problem could have arisen.
따라서 본 발명자들은 이와 같은 PPS 항생 제제에 덱사메타손 혼용 또는 병용으로 인한 대사 장애 및 성장 저해의 문제점을 해결하기 위해 연구하던 중 통상 비타민 B12와 함께 대사촉진제로 사용하는 부타포스판(butaphosphan)을 병용하면 투여 동물의 대사 장애가 극복됨은 물론 성장 촉진 등의 효과가 있음을 발견하고 본 발명을 완성하게 된 것이다.
Therefore, the inventors of the present invention conducted studies to solve the problems of metabolism disorder and growth inhibition caused by the combination or combination of dexamethasone with such PPS antibiotics, and when using butaphosphan, which is usually used as a metabolic accelerator together with vitamin B12, The present inventors have found that there is an effect of overcoming the metabolic disturbance of the animal as well as the promotion of growth and completed the present invention.
따라서 본 발명이 해결하고자 하는 과제는 이와 같은 PPS 항생 제제에 덱사메타손 혼용 또는 병용으로 인한 대사 장애 및 성장 저해의 문제점을 해결하기 위한 것으로, PPS 항생제제, 덱사메타손에 또 다른 약리활성 물질을 함유하는 동물용 복합 기능성 항생제 조성물을 개발하여 투여 동물의 대사 장애 및 성장 저해 문제점을 해결코자 한 것이다.
Accordingly, a problem to be solved by the present invention is to solve the problems of metabolism disorder and growth inhibition due to the combination or use of dexamethasone with such a PPS antibiotic agent, and it is an object of the present invention to provide a PPS antibiotic agent, an animal which contains another pharmacologically active substance in dexamethasone The present inventors have developed a multifunctional antibiotic composition to solve the problem of metabolic disturbance and growth inhibition of the administered animals.
본 발명의 목적은 PPS 항생제제 100 중량부에 대해 0.05?0.5 중량부의 덱사메타손 및 0.5?5 중량부의 부타포스판을 함유하는 페니실린 아나필락시스에 대한 안전성 및 대사기능성을 향상시킨 동물용 복합 기능성 항생제 조성물을 제공하는 것이다.
SUMMARY OF THE INVENTION An object of the present invention is to provide a complex functional antibiotic composition for animals which improves safety and metabolic function against penicillin anaphylaxis containing 0.05 to 0.5 parts by weight of dexamethasone and 0.5 to 5 parts by weight of butaphosphane with respect to 100 parts by weight of PPS antibiotics. It is.
또한 이때 PPS 항생제제 100 중량부에 대해 0.1?0.3 중량부의 덱사메타손 및 1?3 중량부의 부타포스판을 함유함을 특징으로 한다.
In addition, it is characterized in that it contains 0.1 to 0.3 parts by weight of dexamethasone and 1 to 3 parts by weight of butaphosphane relative to 100 parts by weight of the PPS antibiotic.
한편 본 발명의 동물용 복합 기능성 항생제 조성물의 효능 효과는 소, 말, 돼지, 양, 산양, 염소 및 개, 고양이의 폐렴, 파스튜렐라증, 설사, 유방염, 자궁염, 렙토스피라증, 돼지단독, 패혈증 등 페니실린과 스트렙토마이신에 감수성이 있는 세균에 의한 동물 질병의 치료에 사용함을 특징으로 한다.
Meanwhile, the efficacy of the multifunctional antibiotic composition for an animal of the present invention can be effectively utilized in a variety of animals such as cows, horses, pigs, sheep, goats, goats and poultry of dogs and cats, pustulerosis, diarrhea, mastitis, leptospirosis, It is characterized by its use in the treatment of animal diseases caused by bacteria susceptible to penicillin and streptomycin.
한편 본 발명의 동물용 복합 기능성 항생제 조성물은 동물용주사제, 산제, 액제, 과립제, 정제로 제형화됨을 특징으로 한다.
Meanwhile, the multi-functional antibiotic composition for animals of the present invention is characterized in that it is formulated into an animal resuscitation agent, a powder, a solution, a granule, and a tablet.
따라서 본 발명의 효과는 PPS 항생제제, 덱사메타손 및 부타포스판을 함유하는 동물용 복합 기능성 항생제 조성물을 개발함으로써, 이와 같은 PPS 항생 제제에 덱사메타손 혼용 또는 병용으로 인한 대사 장애 및 성장 저해의 문제점을 해결함과 동시에 투여 동물의 대사 장애가 극복됨은 물론 성장 촉진 등의 효과를 제공하기 위한 것이다.
Thus, the effect of the present invention solves the problems of metabolic disturbance and growth inhibition caused by the combination or combination of dexamethasone in such PPS antibiotic agents by developing a multi-functional antibiotic composition for animals containing PPS antibiotic agent, dexamethasone and butafosan And at the same time to overcome the metabolic disturbance of the administered animals as well as to provide effects such as growth promotion.
본 발명에 사용되는 PPS 항생제제는 1987년 농림수산검역검사본부로부터 동물용 의약품으로 허가받고 현재 국내에서 시판되고 있는 동물용 의약품 항생제제로서, 1ml 주사제 내에 벤자틴 페니실린G 수화물(Penicillin G Benzathine Hydrate) 100,000 IU; 프로카인 페니실린G (Penicillin G Procaine) 150,000 IU; 디히드로스트렙토마이신 황산염(Dihydrostreptomycin Sulfate) 200.0 mg(역가) 및 적량의 주사용수로 되어있는 동물용 의약품 항생제제인 것이다.
The PPS antibiotic agent used in the present invention was approved as a veterinary medicine from the Agriculture, Forestry and Fisheries Quarantine and Inspection Headquarters in 1987 and is commercially available as an antibiotic agent for veterinary use in Korea. Penicillin G Benzathine Hydrate is contained in 1 ml injection, 100,000 IU; Penicillin G Procaine 150,000 IU; The dihydrostreptomycin sulfate (Dihydrostreptomycin Sulfate) 200.0 mg (titer) and an appropriate amount of water for injection are animal drugs antibiotics.
한편 본 발명의 또 다른 성분인 덱사메타손은 글루코코르티코이드와 유사한 생리활성을 나타내는 합성 스테로이드의 일종으로 강력한 항염증 작용을 지녀 류머티스성 관절염, 알레르기성 질환 및 피부질환 등의 치료에 사용되는 스테로이드 물질로서 페니실린 아나필락시스의 치료 및 예방을 위해 사용되는 약리활성 물질이다.
Meanwhile, dexamethasone, another component of the present invention, is a kind of synthetic steroid exhibiting a physiological activity similar to glucocorticoid, and has a strong anti-inflammatory action, and is a steroid substance used in the treatment of rheumatoid arthritis, allergic diseases and skin diseases, etc. As penicillin anaphilox And the like.
또한 본 발명의 추가적 성분인 부타포스판은 하기 구조식을 지니는 유기인화합물로서 대사를 활성화하고 면역 시스템을 조절하는 기능을 지닌 약리활성 물질이다.The butafosan, a further component of the present invention, is a pharmacologically active substance having the following structural formula and having the function of activating metabolism and regulating the immune system.
본 발명은 PPS 항생제제 100 중량부에 대해 0.5?10 중량부의 덱사메타손, 0.1?5 중량부의 부타포스판을 함유하는 동물용 복합 기능성 항생제 조성물을 제공하는 것이다.
The present invention provides a composite functional antibiotic composition for animals containing 0.5-10 parts by weight of dexamethasone and 0.1-5 parts by weight of butaphosphane with respect to 100 parts by weight of PPS antibiotic.
더욱 바람직하게는 PPS 항생제제 100 중량부에 대해 1?5 중량부의 덱사메타손, 0.5?3 중량부의 부타포스판을 함유하는 동물용 복합 기능성 항생제 조성물을 제공하는 것이다.
More preferably, to provide a composite functional antibiotic composition for animals containing 1 to 5 parts by weight of dexamethasone, 0.5 to 3 parts by weight of butaphosphane relative to 100 parts by weight of PPS antibiotics.
본 발명의 동물용 복합 기능성 항생제 조성물의 효능 효과는 폐렴, 파스튜렐라증, 설사, 유방염, 자궁염, 렙토스피라증, 돼지단독, 패혈증 등 페니실린과 스트렙토마이신에 감수성이 있는 세균에 의한 동물 질병의 치료에 사용되는 것이다.
The efficacy of the multifunctional antibiotic composition for animals of the present invention is useful for the treatment of animal diseases caused by bacteria susceptible to penicillin and streptomycin, such as pneumonia, pustulerosis, diarrhea, mastitis, hemorrhoids, leptospirosis, .
또한 본 발명의 동물용 복합 기능성 항생제 조성물의 용법 및 용량은 소, 말, 돼지, 양과 같은 가축의 경우 체중 100kg 당 10ml를 48 ~ 72시간마다 근육주사하며 자돈, 어린 양, 개, 고양이의 경우 체중 10kg 당 1ml를 48 ~ 72시간마다 근육주사 하는 것이다.
In addition, the dosage and the dosage of the multi-functional antibiotic composition for animals according to the present invention is such that 10 ml per 100 kg of body weight is injected intramuscularly every 48 to 72 hours for livestock such as cows, horses, pigs and sheep, 1 ml per 10 kg is injected intramuscularly every 48 to 72 hours.
한편 본 발명의 동물용 복합 기능성 항생제 조성물은 해당 기술분야에 통상의 지식을 가진 자가 용이하게 실시할 수 있는 방법으로 동물용주사제, 산제, 액제 또는 과립제, 정제로 제형화될 수 있으며, 예를 들면 동물용 주사제 및 경구용 액제의 경우에는 약제학적으로 허용 가능한 담체로서 증류수, 에틸올레이트, 에탄올, 프로필렌글리콜, 글리세린 등을 사용할 수 있고, 항산화제로서 아스코르빈산, 아황산수소나트륨, 피로아황산나트륨, 토코페롤 등을 사용할 수 있으며, 보존제로서 질산페닐수은, 티메로살, 염화벤잘코늄, 페놀, 크레솔, 파라옥시메틸벤조에이트, 벤질알코올 등을 이용하여 제형화 시킬 수 있다. 또한 동물용 산제 및 과립제의 경우에는 비타민류, 글루코스, 락토스 등의 당류, 전분 또는 각종 분말 및 액상효소를 적량 사용하여 제형화 할 수 있다.
Meanwhile, the multi-functional antibiotic composition for animals of the present invention can be formulated into an animal husbandry powder, a powder, a solution, a granule or a tablet by a method which can be easily carried out by those having ordinary skill in the art, In the case of animal injections and oral liquid preparations, distilled water, ethyl oleate, ethanol, propylene glycol, glycerin and the like can be used as pharmaceutically acceptable carriers. As antioxidants, there can be used ascorbic acid, sodium hydrogen sulfite, sodium pyruvate, Tocopherol, and the like can be used. The preservative can be formulated with phenyl mercuric nitrate, thimerosal, benzalkonium chloride, phenol, cresol, paraoxymethyl benzoate, benzyl alcohol and the like. In the case of animal powders and granules, saccharides such as vitamins, glucose, and lactose, starch, various powders, and liquid enzyme can be formulated in appropriate quantities.
또한 본 발명에 따른 동물용 복합 기능성 항생제 조성물의 투여는 주사제로서는 통상 근육주사의 방법으로 투여되고, 액제의 경우에는 직접 경구 또는 음용수에 혼합하여 투여하고 산제 및 과립제는 음용수 및 사료에 혼합하여 투여한다.
In addition, administration of the multifunctional antibiotic composition for an animal according to the present invention is usually carried out by intramuscular injection as an injection. In the case of a liquid preparation, it is directly mixed with oral or drinking water. Powder and granule are mixed with drinking water and feed .
이하 본 발명을 실시예를 통해 더욱 상세히 설명한다. 그러나 이러한 실시예들로 본 발명의 범위를 한정하는 것은 아니다.
Hereinafter, the present invention will be described in more detail with reference to Examples. However, these embodiments are not intended to limit the scope of the present invention.
(제조실시예 1) 본 발명의 동물용 복합 기능성 항생제 조성물의 제조
(Preparation Example 1) Preparation of the complex functional antibiotic composition for animals of the present invention
1ml 주사제 내에 벤자틴 페니실린G 수화물(KVP) 100,000 IU; 프로카인 페니실린G(KVP) 150,000 IU; 디히드로스트렙토마이신 황산염(KVP) 200.0mg(역가)으로 구성된 PPS 항생제제 100ml에 덱사메타손 0.2g, 부타포스판 2g을 용해시켜 본 발명의 동물용 복합 기능성 항생제 조성물을 제조한다.
100,000 IU of benzathine penicillin G hydrate (KVP) in 1 ml injection; Procain penicillin G (KVP) 150,000 IU; 0.2 g of dexamethasone and 2 g of butafosan are dissolved in 100 ml of a PPS antibiotic composition composed of 200.0 mg (potency) of dihydrostreptomycin sulfate (KVP) to prepare a multifunctional antibiotic composition for animals of the present invention.
(제조실시예 2) 본 발명의 동물용 복합 기능성 항생제 조성물의 제조
(Production Example 2) Production of a complex functional antibiotic composition for animals of the present invention
1ml 주사제 내에 벤자틴 페니실린G 수화물(KVP) 100,000 IU; 프로카인 페니실린G(KVP) 150,000 IU; 디히드로스트렙토마이신 황산염(KVP) 200.0mg(역가)으로 구성된 PPS 항생제제 100ml에 덱사메타손 0.15g, 부타포스판 1.5g을 용해시켜 본 발명의 동물용 복합 기능성 항생제 조성물을 제조한다.
100,000 IU of benzathine penicillin G hydrate (KVP) in 1 ml injection; Procain penicillin G (KVP) 150,000 IU; 0.15 g of dexamethasone and 1.5 g of butafosan are dissolved in 100 ml of a PPS antibiotic agent composed of 200.0 mg (potency) of dihydrostreptomycin sulfate (KVP) to prepare a multifunctional antibiotic composition for animals of the present invention.
(제조실시예 3) 본 발명의 동물용 복합 기능성 항생제 조성물의 제조
(Production Example 3) Production of a complex functional antibiotic composition for animals of the present invention
1ml 주사제 내에 벤자틴 페니실린G 수화물(KVP) 100,000 IU; 프로카인 페니실린G(KVP) 150,000 IU; 디히드로스트렙토마이신 황산염(KVP) 200.0mg(역가)으로 구성된 PPS 항생제제 100ml에 덱사메타손 0.25g, 부타포스판 2.5g을 용해시켜 본 발명의 동물용 복합 기능성 항생제 조성물을 제조한다.
100,000 IU of benzathine penicillin G hydrate (KVP) in 1 ml injection; Procain penicillin G (KVP) 150,000 IU; 0.25 g of dexamethasone and 2.5 g of butafosan are dissolved in 100 ml of a PPS antibiotic agent composed of 200.0 mg (potency) of dihydrostreptomycin sulfate (KVP) to prepare a multifunctional antibiotic composition for animals of the present invention.
(제조비교예 1) 동물용 복합 기능성 항생제 조성물(부타포스판 제외) 제조
(Preparation Comparative Example 1) Production of multi-functional antibiotic composition for animals (except butane force plate)
1ml 주사제 내에 벤자틴 페니실린G 수화물(KVP) 100,000 IU; 프로카인 페니실린G(KVP) 150,000 IU; 디히드로스트렙토마이신 황산염(KVP) 200.0mg(역가)으로 구성된 PPS 항생제제 100ml에 덱사메타손 0.2g을 용해시켜 동물용 복합 기능성 항생제 조성물을 제조한다.
100,000 IU of benzathine penicillin G hydrate (KVP) in 1 ml injection; Procain penicillin G (KVP) 150,000 IU; And 0.2 g of dexamethasone was dissolved in 100 ml of a PPS antibiotic composition consisting of 200.0 mg (potency) of dihydrostreptomycin sulfate (KVP) to prepare a multifunctional antibiotic composition for animals.
(제조비교예 2) 동물용 복합 기능성 항생제 조성물(덱사메타손 증가) 제조
(Preparation Comparative Example 2) Production of multi-functional antibiotic composition for animals (increase in dexamethasone)
1ml 주사제 내에 벤자틴 페니실린G 수화물(KVP) 100,000 IU; 프로카인 페니실린G(KVP) 150,000 IU; 디히드로스트렙토마이신 황산염(KVP) 200.0mg(역가)으로 구성된 PPS 항생제제 100ml에 덱사메타손 2g, 부타포스판 2g을 용해시켜 동물용 복합 기능성 항생제 조성물을 제조한다.
100,000 IU of benzathine penicillin G hydrate (KVP) in 1 ml injection; Procain penicillin G (KVP) 150,000 IU; 2 g of dexamethasone and 2 g of butafosan are dissolved in 100 ml of a PPS antibiotic agent composed of 200.0 mg (potency) of dihydrostreptomycin sulfate (KVP) to prepare a multifunctional antibiotic composition for animals.
(실시예 1) 항생제 MIC 시험
(Example 1) Antibiotic MIC test
제조실시예 1?3, 제조비교예 1?2에서 제조된 동물용 복합 기능성 항생제 조성물을 순차적으로 희석시켜 보데텔라(B. bronchiseptica), 대장균(E. coli K88ab), 살모넬라(S. typhimurium), 파스튜렐라(P. multocida type A) 각각의 균주에 대한 최소 발효 억제 농도(MIC)를 측정하였다. 그 결과를 표 1에 나타내었다.
Botanella ( B. bronchiseptica ), Escherichia coli ( E. coli ) by sequentially diluting the animal complex functional antibiotic composition prepared in Preparation Examples 1 to 3, Comparative Examples 1 to 2 The minimum fermentation inhibitory concentration (MIC) of each strains was determined for each of the strains K88ab, S. typhimurium and P. multocida type A. The results are shown in Table 1.
표 1에 나타난 바와 같이 제조실시예 1?3, 제조비교예 1에서 제조된 동물용 복합 기능성 항생제 조성물의 경우 MIC 상의 유의적 차이는 없었으나 제조비교예 2에서 제조된 동물용 복합 기능성 항생제 조성물의 경우 MIC 수치가 다른 제조실시예 및 제조비교예에서 제조된 동물용 복합 기능성 항생제 조성물 보다 높게 나타났다. 이는 덱사메타손 함량을 기준치 이상으로 증가시킨 경우 항생제의 활성이 저하됨을 나타낸 것이다.
As shown in Table 1, the composite functional antibiotic composition for animals prepared in Preparation Examples 1 to 3 and Comparative Example 1 had no significant difference in MIC, but the composite functional antibiotic composition for animals prepared in Comparative Preparation Example 2 The MIC level was higher than that of the composite functional antibiotic composition for animals prepared in other preparation examples and comparative examples. This indicates that increasing the dexamethasone content above the reference level is reduced antibiotic activity.
(실시예 2) 페니실린 아나필락시스 발생 억제 시험
(Example 2) Penicillin anaphylaxis inhibition test
제조실시예 1?3, 제조비교예 1?2에서 제조된 5종의 동물용 복합 기능성 항생제 조성물을 사용하여 페니실린 아나필락시스 발생 억제 시험을 시행하였다. 시험 방법은 체중 10kg의 이유자돈 250마리를 사용하여 50마리씩 5개의 투여군으로 분리하고 각각의 투여군의 50마리 이유자돈에 대해 각각의 제조실시예 및 제조비교예에서 제조된 5종의 동물용 복합 기능성 항생제 조성물 5ml를 24시간 간격으로 3번 투여하고 페니실린 아나필락시스 발생 유무를 확인하였다. 제조실시예 1?3, 제조비교예 1?2에서 제조된 5종의 동물용 복합 기능성 항생제 조성물을 투여한 모든 250마리의 시험군에서 페니실린 아나필락시스는 발생하지 않았다.
Penicillin anaphylaxis development inhibition test was conducted using five animal complex functional antibiotic compositions prepared in Preparation Examples 1-3 and Comparative Examples 1-2. In the test method, 250 dogs weighing 10 kg were used, and 50 dogs were separated into five administration groups of 50 dogs of each administration group. Five kinds of multi-functional antibiotic composition for animals 5 ml were administered 3 times at 24 hour intervals to confirm the occurrence of penicillin anaphylaxis. Penicillin anaphylaxis did not occur in all 250 test groups administered the five animal complex functional antibiotic compositions prepared in Preparation Examples 1-3 and Comparative Examples 1-2.
(실시예 3) 성장저해 발생 유무 확인 시험
(Example 3) Test for confirming whether growth inhibition occurred
제조실시예 1?3, 제조비교예 1?2에서 제조된 5종의 동물용 복합 기능성 항생제 조성물을 사용하여 성장저해 발생 유무 확인 시험을 시행하였다. 시험 방법은 체중 50kg의 돼지 100마리를 사용하여 20마리씩 5개의 투여군으로 분리하고 각각의 투여군의 20마리 돼지에 대해 각각의 제조실시예 및 제조비교예에서 제조된 5종의 동물용 복합 기능성 항생제 조성물 10ml를 48시간 간격으로 5번 투여하고 정상 급이시키면서 체중 증감 여부를 30일 간 추적 확인하였다. 그 결과를 표 2에 나타내었다.
Using five animal complex functional antibiotic compositions prepared in Preparation Examples 1 to 3 and Comparative Examples 1 and 2, a test for confirming the occurrence of growth inhibition was performed. In the test method, 100 pigs weighing 50 kg were used, and 20 rabbits of 20 rabbits were divided into five administration groups, and the five kinds of multi-functional antibiotic composition for animals prepared in each of the preparation examples and comparative examples 10 ml was administered 5 times at 48 hour intervals and the body weight was monitored for 30 days by normal feeding. The results are shown in Table 2.
제조실시예 1?3, 제조비교예 2에서 제조된 4종의 동물용 복합 기능성 항생제 조성물과 정상 급이를 실시한 투여군에서는 정상적인 체중 증가가 관찰되었으나 제조비교예 1에서 제조된 동물용 복합 기능성 항생제 조성물과 정상 급이를 실시한 투여군에서는 복합 기능성 항생제 조성물 투여 후 15일 내지 30일 이후에 정상적인 체중 증가보다 낮은 체중 증가가 관찰되었다. 이는 제조비교예 1에서 제조된 동물용 복합 기능성 항생제 조성물의 경우 부타포스판을 함유하고 있지 않아 성장저해가 나타남을 의미하는 것이다.
Although the normal weight gain was observed in the four animal complex antibiotic composition prepared in Preparation Examples 1 to 3 and Comparative Example 2 and the normal feeding group, the complex functional antibiotic composition for animals prepared in Comparative Example 1 In the group administered with the normal feeding, a weight gain lower than the normal weight gain was observed after 15 to 30 days after the administration of the complex functional antibiotic composition. This means that the multifunctional antibiotic composition for animals prepared in Preparation Example 1 does not contain a butafosan, which indicates growth inhibition.
(실시예 4) 대사장애 발생 유무 확인 시험
(Example 4) Test for confirming whether or not a metabolic disorder has occurred
제조실시예 1?3, 제조비교예 1?2에서 제조된 5종의 동물용 복합 기능성 항생제 조성물을 사용하여 대사장애 발생 유무를 시험하였다. 시험 방법은 체중 50kg의 돼지 100마리를 사용하여 20마리씩 5개의 투여군으로 분리하고 각각의 투여군의 20마리 돼지에 대해 각각의 제조실시예 및 제조비교예에서 제조된 5종의 동물용 복합 기능성 항생제 조성물 10ml를 48시간 간격으로 5번 투여하고 정상 급이시키면서 흡수도를 설사 발생 유무로 30일 간 추적 확인하였다. 그 결과를 표 2에 나타내었다.
The presence of metabolic disorders was tested using five animal complex functional antibiotic compositions prepared in Preparation Examples 1 to 3 and Comparative Examples 1 and 2. In the test method, 100 pigs weighing 50 kg were used, and 20 rabbits of 20 rabbits were divided into five administration groups, and the five kinds of multi-functional antibiotic composition for animals prepared in each of the preparation examples and comparative examples 10 ml was administered 5 times at intervals of 48 hours, and absorbance was monitored for 30 days with or without diarrhea. The results are shown in Table 2.
실시예 1Produce
Example 1
실시예 2Produce
Example 2
실시예 3Produce
Example 3
비교예 1Produce
Comparative Example 1
비교예 2Produce
Comparative Example 2
체중Average
weight
발생
돼지수diarrhea
Occur
Number of pigs
제조실시예 1?3, 제조비교예 2에서 제조된 4종의 동물용 복합 기능성 항생제 조성물과 정상 급이를 실시한 투여군에서는 20마리의 각각의 투여군 중에서 15일 내지 30일 후에도 설사 발생 개체수가 0 또는 1두로서 대사장애가 발생하지 않았으나, 제조비교예 1에서 제조된 동물용 복합 기능성 항생제 조성물과 정상 급이를 실시한 투여군에서는 15일 내지 30일 후에는 설사 발생 개체수가 2 또는 3두로 증가하여 대사장애가 발생하는 것으로 관찰되었다. 이는 제조비교예 1에서 제조된 동물용 복합 기능성 항생제 조성물의 경우 부타포스판을 함유하고 있지 않아 대사장애가 나타남을 의미하는 것이다.In the administration group subjected to the four animal complex functional antibiotic compositions prepared in Preparation Examples 1 to 3 and Comparative Example 2 and normal feeding, the number of diarrhea generation was 0 or 15 days after 30 to 30 days in each of the 20 administration groups. Metabolic disorders did not occur as a single head, but in the administration group administered with the composite functional antibiotic composition prepared in Comparative Example 1 and normal feeding, the number of diarrhea increased to 2 or 3 heads after 15 to 30 days, resulting in metabolic disorders. Was observed. This means that the multifunctional antibiotic composition for animals prepared in Comparative Preparation Example 1 does not contain butafosan, which means that metabolic disturbance appears.
Claims (4)
Combined functional antibiotic composition for animals with improved safety and metabolic function against penicillin anaphylaxis containing 0.05 to 0.5 parts by weight of dexamethasone and 0.5 to 5 parts by weight of butaphosphane per 100 parts by weight of PPS antibiotic
The complex functional antibiotic composition for animals according to claim 1, which contains 0.1 to 0.3 parts by weight of dexamethasone and 1 to 3 parts by weight of butaphosphane, relative to 100 parts by weight of the PPS antibiotic.
According to claim 1, wherein the efficacy of the combined functional antibiotic composition for animals is pneumonia, pasturela, diarrhea, mastitis, uteritis, leptospirosis, swine alone of cattle, horses, pigs, sheep, goats, goats and dogs, cats Functional antibiotic composition for animals, characterized in that used for the treatment of animal diseases caused by bacteria susceptible to penicillin and streptomycin, such as sepsis
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020120109818A KR101400791B1 (en) | 2012-10-04 | 2012-10-04 | Functional antibiotic complex composition for animal use |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020120109818A KR101400791B1 (en) | 2012-10-04 | 2012-10-04 | Functional antibiotic complex composition for animal use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20120117715A true KR20120117715A (en) | 2012-10-24 |
| KR101400791B1 KR101400791B1 (en) | 2014-05-29 |
Family
ID=47285578
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020120109818A KR101400791B1 (en) | 2012-10-04 | 2012-10-04 | Functional antibiotic complex composition for animal use |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR101400791B1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20180080142A (en) * | 2017-01-03 | 2018-07-11 | 서울대학교산학협력단 | Therapeutic composition of bovine mastitis |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102619907B1 (en) * | 2015-08-17 | 2024-01-02 | 서화수 | Combination composition for treatment of diarrhea in calf |
| KR102086462B1 (en) * | 2018-08-01 | 2020-03-09 | 주식회사대성미생물연구소 | Antibiotics complex composition for veterinary treatment of multiple respiratory diseases |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5683993A (en) | 1995-06-22 | 1997-11-04 | Ciba Vision Corporation | Compositions and methods for stabilizing polymers |
| DE102007012644A1 (en) * | 2007-03-16 | 2008-09-18 | Bayer Healthcare Ag | Stabilization of vitamin B12 |
| JP5554702B2 (en) * | 2007-06-05 | 2014-07-23 | パカ パルモナリー ファーマシューティカルズ， インコーポレイテッド | Methods and compositions for delivering drugs to the lung |
| DE102008022520A1 (en) * | 2008-05-07 | 2009-11-12 | Bayer Animal Health Gmbh | Solid sustained-release pharmaceutical formulation |
-
2012
- 2012-10-04 KR KR1020120109818A patent/KR101400791B1/en active IP Right Grant
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20180080142A (en) * | 2017-01-03 | 2018-07-11 | 서울대학교산학협력단 | Therapeutic composition of bovine mastitis |
Also Published As
| Publication number | Publication date |
|---|---|
| KR101400791B1 (en) | 2014-05-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Botsoglou et al. | Drug residues in foods | |
| KR101400791B1 (en) | Functional antibiotic complex composition for animal use | |
| JP2023503437A (en) | Use of SGLT-2 inhibitors in dry milk of non-human animals | |
| NZ542379A (en) | Compositions for treating microbial and parasitic infections in cattle and other animals | |
| EP3071210B1 (en) | Stress management in livestock | |
| DE3153623C2 (en) | ||
| RU2487709C2 (en) | Compositional preparation for treating pneumonia in piglets | |
| KR20200038435A (en) | Antibiotics composition for animals | |
| US9049874B2 (en) | Use of azaperone for reducing antibiotic usage | |
| Behlke et al. | Comparative efficacy of ceftiofur crystalline free acid and florfenicol-flunixin meglumine for undifferentiated fever treatment in feedlot calves administered tulathromycin metaphylactically on arrival | |
| US3790669A (en) | Synergistic tylosin and furazolidone medication for calf pneumoenteritis complex | |
| CN113318106B (en) | Long-acting compound amoxicillin oil suspension injection for animals and preparation method thereof | |
| US20220175707A1 (en) | Pregabalin formulations and use thereof | |
| US4123522A (en) | Control of bloat in ruminants | |
| RU2530619C1 (en) | Method of prevention of pneumonia in piglets | |
| KR102058133B1 (en) | Composition for enhancing immune activity capable of improving of solubility of antibiotics in mixed formulation and use thereof | |
| US2797182A (en) | Cadmium anthranilate containing anthelmintics | |
| Papich | Drug therapy and selection in exotic medicine. | |
| EP0597167A1 (en) | Veterinary preparation containing an antibiotic mixture of gentamicin and lincomycin as an additive to drinking water or animal feed and its use in pig breeding | |
| KR960015952B1 (en) | Antidiarrheial therapeutic agents for animal and the pharmaceutical compositions comprising them | |
| RU2560667C2 (en) | Method for preventing pneumonia in piglets | |
| KR20230064744A (en) | Composition for chewable veterinary application | |
| CN118267361A (en) | Compound amoxicillin soluble powder for livestock | |
| JPH0291026A (en) | Method for preventing and treating liver tumor of animal and animal feed composition | |
| JP2013223481A (en) | Milk quality improver for livestock |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| E701 | Decision to grant or registration of patent right | ||
| GRNT | Written decision to grant | ||
| FPAY | Annual fee payment |
Payment date: 20170511 Year of fee payment: 4 |
|
| FPAY | Annual fee payment |
Payment date: 20180518 Year of fee payment: 5 |
|
| FPAY | Annual fee payment |
Payment date: 20190610 Year of fee payment: 6 |